中国新药杂志

维莫非尼致皮肤系统不良反应的文献计量学研究分析

PDF下载

尹月 ¹ , 邱新野 ² , 张艳华 ¹

中国新药杂志 | 药物安全与合理应用 2021,30(22): 2116-2120

收起

中国新药杂志 |药物安全与合理应用 2021 , 30 (22) : 2116 -2120

维莫非尼致皮肤系统不良反应的文献计量学研究分析

全屏

[Author(id=1322125576375222851, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=yinyue_1108@sina.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322125576572355141, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, authorId=1322125576375222851, language=EN, stringName=Yue YIN, firstName=Yue, middleName=null, lastName=YIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Department of Pharmacy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing 100142, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322125576656241222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, authorId=1322125576375222851, language=CN, stringName=尹月, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142, bio={"content":"

尹月，女，硕士研究生，研究方向：肿瘤临床药学。联系电话：(010)88196338，E-mail：yinyue_1108@sina.com。

"}, bioImg=null, bioContent=

尹月，女，硕士研究生，研究方向：肿瘤临床药学。联系电话：(010)88196338，E-mail：yinyue_1108@sina.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322125576140341820, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, xref=1, ext=[AuthorCompanyExt(id=1322125576152924733, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, companyId=1322125576140341820, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Pharmacy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing 100142, China), AuthorCompanyExt(id=1322125576165507646, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, companyId=1322125576140341820, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142)])]), Author(id=1322125576769487432, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322125576870150730, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, authorId=1322125576769487432, language=EN, stringName=Xin-ye QIU, firstName=Xin-ye, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322125576945648203, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, authorId=1322125576769487432, language=CN, stringName=邱新野, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=²首都医科大学附属北京佑安医院药学中心，北京　100069, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322125576245199423, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, xref=2, ext=[AuthorCompanyExt(id=1322125576257782336, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, companyId=1322125576245199423, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China), AuthorCompanyExt(id=1322125576266170945, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, companyId=1322125576245199423, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=²首都医科大学附属北京佑安医院药学中心，北京　100069)])]), Author(id=1322125577012757069, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zyh8812@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322125577109226063, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, authorId=1322125577012757069, language=EN, stringName=Yan-hua ZHANG, firstName=Yan-hua, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹Department of Pharmacy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing 100142, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322125577214083664, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, authorId=1322125577012757069, language=CN, stringName=张艳华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322125576140341820, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, xref=1, ext=[AuthorCompanyExt(id=1322125576152924733, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, companyId=1322125576140341820, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹Department of Pharmacy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing 100142, China), AuthorCompanyExt(id=1322125576165507646, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322125575255343673, companyId=1322125576140341820, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142)])])]

尹月¹, 邱新野², 张艳华¹

作者信息

¹北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142

²首都医科大学附属北京佑安医院药学中心，北京　100069

通讯作者:

张艳华，女，硕士生导师，研究方向：医院药学。联系电话：(010)88196960，E-mail：zyh8812@163.com。

作者简介:

尹月，女，硕士研究生，研究方向：肿瘤临床药学。联系电话：(010)88196338，E-mail：yinyue_1108@sina.com。

Bibliometric analysis of adverse drug reactions of vemurafenib

Yue YIN¹, Xin-ye QIU², Yan-hua ZHANG¹

Affiliations

¹Department of Pharmacy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Beijing 100142, China

²Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

出版时间: 2021-11-30

文章导航

摘要

收起

目的：

分析维莫非尼所致皮肤系统不良反应发生情况及临床特点，为临床安全用药提供参考。

方法：

检索Web of Science、PubMed、中国知网数据库、维普数据库、万方数据关于维莫非尼皮肤系统不良反应（ADRs）的文献并进行分析总结。

结果：

维莫非尼致皮肤系统毒性的ADRs的个案报道共41例次；其年龄分布以41~70岁年龄段较多（25例，61.0%）；多发生在用药后15 d内（22例，53.7%）；维莫非尼致皮肤系统ADRs主要临床表现为脂膜炎（12例，29.3%）、白细胞破碎性血管炎（6例，14.6%）、肉芽肿性皮炎（5例，12.2%）、光敏性皮炎（4例，9.8%）、放射性皮炎（3例，7.3%）及皮肤角化过度（3例，7.3%）；34例在出现ADRs后痊愈或好转，其中27例（65.9%）重新恢复维莫非尼治疗，7例停药，出现的ADRs分别为肉芽肿性皮炎（2例）、中毒性表皮坏死松解（1例）、皮肤血管炎（2例）及光敏性皮炎（2例）。重启治疗的患者中，21例维持原剂量，5例减至3/4原剂量，1例剂量减半，9例患者未再次发生ADRs。

结论：

临床使用维莫非尼时应加强用药监测，尤其警惕用药后15 d内ADRs的发生，及时发现潜在ADRs并采取适当防治措施，同时应慎重评估重启给药后的治疗风险。

关键词

维莫非尼 / 不良反应 / 回顾性分析 / 用药安全

Abstract

收起

Objective:

To analyze the occurrence and clinical characteristics of skin adverse reactions caused by vemurafenib, and provide reference for clinical safe drug use.

Methods:

The literatures about skin adverse reactions of vemurafenib were retrieved from Web of Science, PubMed, CNKI, VIP database and Wanfang data, and then analyzed and summarized.

Results:

A total of 41 cases of ADRs induced by vemurafenib were reported. Most of them aged from 41 to 70 years old (n=25, 61.0%). Most of them occurred within 15 d after medication (n=22, 53.7%). The main clinical manifestations of skin system ADRs induced by vemurafenib were lipiditis (12 cases, 29.3%), leukocytoclastic vasculitis (n=6, 14.6%), granulomatous dermatitis (n=5, 12.2%), photosensitive dermatitis (n=4, 9.8%), radioactive dermatitis (n=3, 7.3%), and hyperkeratosis (n=3, 7.3%). Thirty-four cases were cured or improved after ADRs, of whom 27 cases (65.9%) resumed vemurafenib treatment, and 7 cases discontinued, including granulomatous dermatitis (2 cases), toxic epidermal necrolysis (1 case), cutaneous vasculitis (2 cases), and photosensitive dermatitis (2 cases). Among the 27 patients who restarted vemurafenib treatment, 21 cases maintained the original dose, 5 cases reduced the original dose to 3/4, 1 case reduced the original dose by half, and ADRs occurred again in 9 patients.

Conclusion:

Drug monitoring should be strengthened during the clinical use of vemurafenib, especially for the occurrence of ADR within 15 d after drug administration, potential ADRs should be detected in time, appropriate prevention and treatment measures should be taken, and the treatment risk after resumption of treatment should be carefully evaluated.

Key words

vemurafenib / adverse reactions / retrospective analysis / safety of drug use

引用本文

尹月, 邱新野, 张艳华. 维莫非尼致皮肤系统不良反应的文献计量学研究分析. 中国新药杂志, 2021 , 30 (22) : 2116 -2120 .

Yue YIN, Xin-ye QIU, Yan-hua ZHANG. Bibliometric analysis of adverse drug reactions of vemurafenib[J]. Chinese Journal of New Drugs, 2021 , 30 (22) : 2116 -2120 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

BOUSSEMART L, BOIVIN C, CLAVEAU J, et al. Vemurafenib and radiosensitization[J]. JAMA Dermatol, 2013, 149(7): 855-857.

[2]

JEW OS, PROVINI LE, TREAT JR. Severe vemurafenib-induced photosensitivity in a 6-year-old boy[J]. Pediatr Dermatol, 2019, 36(1): e62-e63.

[3]

HUI ONG EL, SINHA R, JMOR S, et al. BRAF inhibitor-associated granulomatous dermatitis: a report of 3 cases[J]. Am J Dermatopathol, 2019, 41(3): 214-217.

[4]

THIEM A, MERGLER R, KNEITZ H, et al. Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy[J]. J Dtsch Dermatol Ges, 2016, 14(4): 427-428.

[5]

ELOSUA-GONZALEZ M, LOPEZ-ESTEBARANZ JL, GARCIA-ZAMORA E, et al. Reaccion acneiforme noduloquistica secundaria a vemurafenib con Buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin[J]. Dermatol Online J, 2018, 24(8): 24(8): 13030.

[6]

BELLÓN T, LERMA V, GONZÁLEZ-VALLE O, et al. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds[J]. Br J Dermatol, 2016, 174(3): 621-624.

[7]

CONEN K, MOSNA-FIRLEJCZYK K, ROCHLITZ C, et al. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature[J]. Dermatology, 2015, 230(1): 1-4.

[8]

SAMMUT SJ, TOMSON N, CORRIE P. Pyogenic granuloma as a cutaneous adverse effect of vemurafenib[J]. N Engl J Med, 2014, 371(13): 1265-1267.

[9]

KOMORI T, OTSUKA A, KAKU Y, et al. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment[J]. J Eur Acad Dermatol Venereol, 2017, 31(10): e474-e475.

[10]

YU JD, RAVIKUMAR S, PLAZA JA, et al. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib[J]. Am J Dermatopathol, 2015, 37(5): e57-e60.

[11]

WEST ES, WILLIAMS VL, MORELLI JG. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma[J]. Pediatr Dermatol, 2015, 32(1): 153-154.

[12]

YIN VT, WIRASZKA TA, TETZLAFF M, et al. Cutaneous eyelid neoplasms as a toxicity of vemurafenib therapy[J]. Ophthalmic Plast Reconstr Surg, 2015, 31(4): e112-e115.

[13]

MIROUSE A, SAVEY L, DOMONT F, et al. Systemic vasculitis associated with vemurafenib treatment: Case report and literature review[J]. Medicine (Baltimore), 2016, 95(46): e4988.

[14]

BOUDEWIJNS S, GERRITSEN WR, KOORNSTRA RH. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma[J]. BMC Cancer, 2014, 14: 967.

[15]

VÁZQUEZ-OSORIO I, SÁNCHEZ-AGUILAR MD, GARCÍA-RODIÑO S, et al. Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature[J]. Am J Dermatopathol, 2016, 38(7): e93-e96.

[16]

BÜYÜKKAPU BAY S, KEBUDI R, ZÜLFIKAR B. Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency[J]. Melanoma Res, 2019, 29(1): 99-101.

[17]

GEY A, MILPIED B, DUTRIAUX C, et al. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?[J]. J Eur Acad Dermatol Venereol, 2016, 30(1): 178-179.

[18]

HERMS F, FRANCK N, KRAMKIMEL N, et al. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event[J]. Br J Dermatol, 2017, 176(6): 1645-1648.

[19]

MCARTHUR GA, CHAPMAN PB, ROBERT C, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study[J]. Lancet Oncol, 2014, 15(3): 323-332.

[20]

KLAEGER S, GOHLKE B, PERRIN J, et al. Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors[J]. ACS Chem Biol, 2016, 11(5): 1245-1254.

[21]

DUMMER R, RINDERKNECHT J, GOLDINGER SM. Ultraviolet A and photosensitivity during vemurafenib therapy[J]. N Engl J Med, 2012, 366(5): 480-481.

[22]

BOUSSEMART L, BOIVIN C, CLAVEAU J, et al. Vemurafenib and radiosensitization[J]. JAMA Dermatol, 2013, 149(7): 855-857.

2021年第30卷第22期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-11-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-06-06

基金

作者信息

¹北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京　100142

²首都医科大学附属北京佑安医院药学中心，北京　100069

通讯作者:

张艳华，女，硕士生导师，研究方向：医院药学。联系电话：(010)88196960，E-mail：zyh8812@163.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322125575255343673

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT